<DOC>
	<DOCNO>NCT00146328</DOCNO>
	<brief_summary>The objective study determine long term safety tolerability multiple oral dos tipranavir ( Aptivus ) ritonavir focus long term safety development dose ( 500 mg tipranavir/200 mg ritonavir BID ) administer antiretroviral medication .</brief_summary>
	<brief_title>Rollover Trial Safety Tolerability Combination Tipranavir Ritonavir Use HIV 1 Infected Subjects</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<criteria>INCLUSION CRITERIA 1 . Ability willingness give write informed consent accordance institutional federal guideline comply investigational nature study related requirement . 2 . All subject must successfully complete participation combination tipranavir/ritonavir trial confirm virologic failure 1182.12 1182.48 trial able obtain TPV prescription . Successful completion participation define conclusion require subjectweeks assign dose ( trial specific ) completion require visit . 3 . Male female subject 18 year . 4 . Presence Human Immunodeficiency Virus 1 ( HIV1 ) infection document licensed Enzyme Linked immunosorbent Assay ( ELISA ) test kit confirm Western Blot , HIV1 culture , HIV1 antigen , plasma HIV 1 Ribonucleic Acid ( RNA ) second antibody test method ELISA time prior study entry . 5 . Adherence previous tipranavir/ritonavir dose protocol adherence visit requirement previous protocol ( assessed principal investigator ) . 6 . Acceptable screen laboratory value indicate adequate baseline organ function . Laboratory value consider acceptable follow apply : Total Cholesterol ≤400 mg/dl ( &lt; Common Toxicity Criteria ( CTC ) Grade 2 ) . Total Triglycerides ≤750 mg/dl ( &lt; Division AIDS ( DAIDS ) Grade 2 ) . Alanine aminotransferase ( ALT ) ≤3.0x upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) ≤2.5x ULN ( &lt; DAIDS Grade 1 ) . Any Grade Gamma Glutamyl transpeptidase ( GGT ) acceptable . Any Grade creatinine kinase acceptable long concurrent myopathy . All laboratory test value ≤DAIDS Grade 1 . EXCLUSION CRITERIA 1 . Female subject reproductive potential : Have positive serum beta human chorionic gonadotropin ( B HCG ) Screening/Enrollment Visit . Are willing use reliable method barrier contraception ( diaphragm condom ) . Are breastfeed . 2 . Subjects actively use injection drug substance abuse ( extensive alcohol narcotic use ) consider investigator significant impairment health protocol adherence . 3 . Any medical condition ( ) , opinion investigator , would interfere subject 's ability participate adhere requirement protocol . 4 . History illness drug allergy , opinion investigator , might confound result study pose additional risk administer tipranavir/ritonavir subject . 5 . Active use following : Investigational HIV1 vaccine . Any new investigational antiretroviral agent approve use patient prior tipranavir trial . Medications exclude trial period ( see Section 4.2 ) . Herbal medication ( e.g. , St. John 's Wort ) . 6 . Active HIVrelated non HIVrelated illness may negatively affect use tipranavir/ritonavir determine investigator . If subject must temporarily discontinue tipranavir/ritonavir recommendation investigator ( completion previous tipranavir trial ) , subject may enroll 1182.17 clinical illness resolve , approval Boehringer Ingelheim Clinical Monitor Local Clinical Monitor . 7 . Clinically significant liver disease 90 day prior baseline visit , regardless baseline AST and/or ALT value . 8 . Hypersensitivity tipranavir ritonavir . 9 . Voluntary discontinuation antiretroviral therapy ( include tipranavir/ritonavir ) seven day completion previous tipranavir trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>